Lipids: A key player in the battle between the host and microorganisms

Journal of Lipid Research

Volumn 53, Issue 12, 2012, Pages 2487-2489

  Feingold, Kenneth R ^a   Grunfeld, Carl ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYTOKINE; LIPID;

ANTIGEN PRESENTATION; CHOLESTEROL BLOOD LEVEL; CYTOKINE PRODUCTION; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; HYPERCHOLESTEROLEMIA; LEISHMANIA DONOVANI; LIPOPROTEIN METABOLISM; MACROPHAGE; MICROORGANISM; NONHUMAN; NOTE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; VISCERAL LEISHMANIASIS;

ANIMALS; CELL MEMBRANE; CHOLESTEROL; HYPERLIPIDEMIAS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL;

EID: 84869052032     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E033407     Document Type: Note

References (26)

1. Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196. (Pubitemid 38802622)
2. Netea, M. G., L. A. Joosten, M. Keuter, F. Wagener, A. F. Stalenhoef, J. W. van der Meer, and B. J. Kullberg. 2009. Circulating lipoproteins are a crucial component of host defense against invasive Salmonella typhimurium infection. PLoS ONE. 4: e4237.
3. Horswill, A. R., and W. M. Nauseef. 2008. Host interception of bacterial communication signals. Cell Host Microbe. 4: 507-509. (Pubitemid 352762960)
4. Peterson, M. M., J. L. Mack, P. R. Hall, A. A. Alsup, S. M. Alexander, E. K. Sully, Y. S. Sawires, A. L. Cheung, M. Otto, and H. D. Gresham. 2008. Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection. Cell Host Microbe. 4: 555-566. (Pubitemid 352762953)
5. Pays, E., B. Vanhollebeke, L. Vanhamme, F. Paturiaux-Hanocq, D. P. Nolan, and D. Perez-Morga. 2006. The trypanolytic factor of human serum. Nat. Rev. Microbiol. 4: 477-486. (Pubitemid 43771867)
6. Feingold, K. R., and C. Grunfeld. 2010. The acute phase response inhibits reverse cholesterol transport. J. Lipid Res. 51: 682-684.
7. Syed, G. H., Y. Amako, and A. Siddiqui. 2010. Hepatitis C virus hijacks host lipid metabolism. TEM. 21: 33-40.
8. Ye, J. 2012. Hepatitis C virus: a new class of virus associated with particles derived from very low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 32: 1099-1103.
9. Bassendine, M. F., D. A. Sheridan, D. J. Felmlee, S. H. Bridge, G. L. Toms, and R. D. Neely. 2011. HCV and the hepatic lipid pathway as a potential treatment target. J. Hepatol. 55: 1428-1440.
10. Hofer, F., M. Gruenberger, H. Kowalski, H. Machat, M. Huettinger, E. Kuechler, and D. Blaas. 1994. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc. Natl. Acad. Sci. USA. 91: 1839-1842. (Pubitemid 24080301)
11. Bashmakov, Y. K., N. A. Zigangirova, A. L. Gintzburg, P. A. Bortsov, and I. M. Petyaev. 2010. ApoB-containing lipoproteins promote infectivity of chlamydial species in human hepatoma cell line. World J. Hepatol. 2: 74-80.
12. Carette, J. E., M. Raaben, A. C. Wong, A. S. Herbert, G. Obernosterer, N. Mulherkar, A. I. Kuehne, P. J. Kranzusch, and A. M. Griffin, et al. 2011. Brummelkamp. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 477: 340-343.
13. Miller, E. H., G. Obernosterer, M. Raaben, A. S. Herbert, M. S. Deffieu, A. Krishnan, E. Ndungo, R. G. Sandesara, J. E. Carette, and A. I. Kuehne, et al. 2012. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. 31: 1947-1960.
14. Martens, G. W., M. C. Arikan, J. Lee, F. Ren, T. Vallerskog, and H. Kornfeld. 2008. Hypercholesterolemia impairs immunity to tuberculosis. Infect. Immun. 76: 3464-3472.
15. Van der Geize, R., K. Yam, T. Heuser, M. H. Wilbrink, H. Hara, M. C. Anderton, E. Sim, L. Dijkhuizen, J. E. Davies, W. W. Mohn, et al. 2007. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc. Natl. Acad. Sci. USA. 104: 1947-1952. (Pubitemid 46239884)
16. Coppens, I., A. P. Sinai, and K. A. Joiner. 2000. Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. J. Cell Biol. 149: 167-180. (Pubitemid 30196707)
17. Portugal, L. R., L. R. Fernandes, V. S. Pietra Pedroso, H. C. Santiago, R. T. Gazzinelli, and J. I. Alvarez-Leite. 2008. Influence of low-density lipoprotein (LDL) receptor on lipid composition, inflammation and parasitism during Toxoplasma gondii infection. Microbes Infect. 10: 276-284.
18. Sonda, S., L. M. Ting, S. Novak, K. Kim, J. J. Maher, R. V. Farese, Jr., and J. D. Ernst. 2001. Cholesterol esterification by host and parasite is essential for optimal proliferation of Toxoplasma gondii. J. Biol. Chem. 276: 34434-34440. (Pubitemid 37384430)
19. Wunder, C., Y. Churin, F. Winau, D. Warnecke, M. Vieth, B. Lindner, U. Zahringer, H. J. Mollenkopf, E. Heinz, and T. F. Meyer. 2006. Cholesterol glucosylation promotes immune evasion by Helicobacter pylori. Nat. Med. 12: 1030-1038. (Pubitemid 44353384)
20. Ghosh, J., S. Das, R. Guha, D. Ghosh, K. Naskar, A. Das, and S. Roy. Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol. J. Lipid Res. 53: 2560-2572.
21. Chappuis, F., S. Sundar, A. Hailu, H. Ghalib, S. Rijal, R. W. Peeling, J. Alvar, and M. Boelaert. 2007. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5: 873-882. (Pubitemid 47578388)
22. Chakraborty, D., S. Banerjee, A. Sen, K. K. Banerjee, P. Das, and S. Roy. 2005. Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. J. Immunol. 175: 3214-3224. (Pubitemid 41170542)
23. Rub, A., R. Dey, M. Jadhav, R. Kamat, S. Chakkaramakkil, S. Majumdar, R. Mukhopadhyaya, and B. Saha. 2009. Cholesterol depletion associated with Leishmania major infection alters macrophage CD40 signalosome composition and effector function. Nat. Immunol. 10: 273-280.
24. Banerjee, S., J. Ghosh, S. Sen, R. Guha, R. Dhar, M. Ghosh, S. Datta, B. Raychaudhury, K. Naskar, and A. K. Haldar, et al. 2009. Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infect. Immun. 77: 2330-2342.
25. Ghosh, J., C. S. Lal, K. Pandey, V. N. Das, P. Das, K. Roychoudhury, and S. Roy. 2011. Human visceral leishmaniasis: decrease in serum cholesterol as a function of splenic parasite load. Ann. Trop. Med. Parasitol. 105: 267-271.
26. Lal, C. S., N. Verma, V. N. Rabidas, A. Ranjan, K. Pandey, R. B. Verma, D. Singh, S. Kumar, and P. Das. 2010. Total serum cholesterol determination can provide understanding of parasite burden in patients with visceral leishmaniasis infection. Clin. Chim. Acta. 411: 2112-2113.